Table 1 Comparison of clinical features between female RA and controls.

Age (year)

55.49 ± 12.33

54.96 ± 10.74

0.397

0.692

Height (cm)

157.76 ± 5.16

157.88 ± 6.24

–2.168

0.031*

Weight (kg)

55.75 ± 10.14

58.13 ± 8.60

–0.181

0.857

disease duration (year)

9.56 ± 9.19

–

–

–

BMI (kg/m²)

22.38 ± 3.81

–

–

–

GCs% (n)/daily dose range in mg

56.4 (110)/4.83 ± 5.29

–

–

–

csDMARDs% (n)

41.54 (81)

–

–

–

DAS28

5.48 ± 1.15

–

–

–

Low-moderate disease activity% (n)

40.5 (79)

–

–

–

High disease activity% (n)

59.5 (116)

–

–

–

HAQ

1.24 ± 0.72

–

–

–

ESR (mm/H)

63.26 ± 29.30

–

–

–

CRP (mg/L)

42.79 ± 46.52

–

–

–

Sharp

61.10 ± 69.38

–

–

–

SMI (kg/m²)

5.37 (4.67–6.03)

8.48 (7.89–8.96)

123.924

< 0.0001*

BBS

44 (31–51)

52 (48–54)

46.023

< 0.0001*

Neck-BMD (g/cm²)

0.79 ± 0.18

0.92 ± 0.16

6.451

< 0.0001*

Hip-BMD (g/cm²)

0.81 ± 0.17

0.97 ± 0.15

9.101

< 0.0001*

L1-BMD (g/cm²)

0.89 ± 0.17

0.98 ± 0.18

6.135

< 0.0001*

L2-BMD (g/cm²)

0.92 ± 0.19

1.06 ± 0.20

6.135

< 0.0001*

L3-BMD (g/cm²)

1.00 ± 0.20

1.13 ± 0.20

5.470

< 0.0001*

L4-BMD (g/cm²)

1.02 ± 0.19

1.13 ± 0.20

5.090

< 0.0001*

L1-4-BMD (g/cm²)

0.98 ± 0.20

1.11 ± 0.20

5.780

< 0.0001*